BG Medicine Layoffs Cut Company Headcount in Half; Firm Receives Nasdaq Warning | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said in a document filed yesterday with the US Securities and Exchange Commission that it has laid off 12 of its 22 employees, or roughly 55 percent of its workforce.

The company said it took this step "in order to reduce its operating expenses and extend its cash runway in anticipation of the commercial launch of automated versions of [its] galectin-3 test," which it plans to launch in the US in 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.